-
Mashup Score: 0Impossible Curbside at Medical Grand Rounds - 2 year(s) ago
Scene: Medical Grand Rounds, 5 minutes before the start. Lecture is on coronary artery disease, which may have a link to Infectious Disease even if it isn’t actually caused by Chlamydia pneumoniae or CMV after all. A well-regarded, experienced primary care physician (PCP) approaches. PCP: Hi Paul, I have quick question*. [*Curbsiders often use this exact phrase — and rarely does […]
Source: HIV and ID ObservationsCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0
In the last post, I cited examples of patients who are doing much better now because they are on long-acting cabotegravir-rilpivirine (CAB-RPV). One of these patients said he preferred it because it’s “simpler,” by which he meant he no longer had to go to the pharmacy to refill his medications each month. I’ll grant for him […]
Source: HIV and ID ObservationsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In the latest HIV and ID Observations post, @PaulSaxMD wraps up a two-part series on long-acting cabotegravir-rilpivirine with a look at the drugs' limitations. https://t.co/kbOFMmhp9q #IDTwitter https://t.co/g5TpN9fhCL
-
-
Mashup Score: 21
In the last post, I cited examples of patients who are doing much better now because they are on long-acting cabotegravir-rilpivirine (CAB-RPV). One of these patients said he preferred it because it’s “simpler,” by which he meant he no longer had to go to the pharmacy to refill his medications each month. I’ll grant for him […]
Source: HIV and ID ObservationsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Now for Part 2, The Limitations CAB-RPV. Of course it isn't perfect -- this is the very first long-acting ART option, and the fact that we have it at all is remarkable. The Yin and the Yang of Cabotegravir-Rilpivirine: Part Two, the Limitations https://t.co/s4jAG15R0y
-
-
Mashup Score: 10Advice to Incoming Subspecialty Fellows -- Don't Underestimate or Belittle Your Interns and Residents - 2 year(s) ago
Around a million years ago, early during the first year of my ID fellowship, a medical intern consulted me about an elderly patient with a urinary tract infection. Me: Does she have a catheter? Intern: I don’t know. Me: Has she been admitted before with a UTI? Any cultures? Intern: I think so — wait, I’m […]
Source: HIV and ID ObservationsCategories: Healthcare Professionals, Latest HeadlinesTweet-
As the first-year @bwh_id @mgh_id fellows officially start this week, I'm re-upping this post, which gives some *very* important advice. Namely: Don’t Underestimate or Belittle Your Interns and Residents https://t.co/a95lT9rcAV
-
-
Mashup Score: 0
Long-acting cabotegravir-rilpivirine (CAB-RPV) is the biggest advance in HIV therapeutics in years. It’s also creating quite the challenge for ID and HIV clinicians, which makes its availability a fascinating example of the importance of education, patient communication, and shared decision-making. This post will be the good news about this groundbreaking treatment; in the next post, I’ll […]
Source: HIV and ID ObservationsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Long-acting cabotegravir-rilpivirine is the biggest advance in HIV therapeutics in years, writes @PaulSaxMD. He begins a two-part series on its pros and cons in the latest HIV and ID Observations post. https://t.co/WaHvq1Kpi8 #IDtwitter https://t.co/b9pBZAAy3C
-
-
Mashup Score: 1
Long-acting cabotegravir-rilpivirine (CAB-RPV) is the biggest advance in HIV therapeutics in years. It’s also creating quite the challenge for ID and HIV clinicians, which makes its availability a fascinating example of the importance of education, patient communication, and shared decision-making. This post will be the good news about this groundbreaking treatment; in the next post, I’ll […]
Source: HIV and ID ObservationsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Long-acting cabotegravir-rilpivirine (CAB-RPV) is the biggest advance in HIV therapeutics in years. Here's a brief explainer why, and a killer classic movie clip. (Next up -- the limitations of this groundbreaking treatment, because there are plenty.) https://t.co/U4Hulp2mod
-
-
Mashup Score: 0
One of the true joys of practicing at academic medical centers is working alongside great clinical teachers. No one exemplified this talented group better than Dr. Martin (Marty) Samuels, former chief of neurology at Brigham and Women’s Hospital (where I work), and professor of neurology at Harvard Medical School. He was quite simply the best clinical […]
Source: HIV and ID ObservationsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
.@PaulSaxMD shares some thoughts on the legacy of Dr. Martin (Marty) Samuels, the Founding Editor of NEJM Journal Watch Neurology and its Editor-in-Chief from 1999 to 2010, who recently passed away. https://t.co/9R8gAz1dDm https://t.co/Ra6750V6Vu
-
-
Mashup Score: 3Three Effective Treatments for COVID-19 Not in Treatment Guidelines -- at Least Not Yet - 2 year(s) ago
A few weeks ago, in a patented (and copyrighted and trademarked) Really Rapid Review™, I summarized some of the Greatest Hits from CROI 2023. The conference included new data on not just HIV, but also a grab bag of opportunistic infections, STIs, viral hepatitis — and, as has been the case since 2020, COVID-19. You know, […]
Source: HIV and ID ObservationsCategories: Endocrinology, Latest HeadlinesTweet-
Ventura-Lopez; Parthasarathy,) Participants voluntarily collected viral load samples in the COVID-OUT trial, and I presented this data at @CROI_2023, a nice summary by Paul Sax https://t.co/UwPc3bCjIr and our preprint is now live as well
-
-
Mashup Score: 5Fifteen Years Later, Why I'm Still Writing This - 2 year(s) ago
Seems like just yesterday that my wonderful editors at NEJM Journal Watch helped me write a piece marking this site’s 10-year anniversary. But no — that was 5 years ago. Yikes. Let’s see, what happened since the spring of 2018 that is relevant to this place: 216 posts. According to our crack research team, that’s one every 8.449074 […]
Source: HIV and ID ObservationsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
HIV and ID Observations launched 15 years ago. @PaulSaxMD reflects on recent events in the infectious diseases field and why he still writes these posts. https://t.co/KqrmxmXiYS #IDTwitter https://t.co/kEOfuW07ks
-
-
Mashup Score: 1Fifteen Years Later, Why I'm Still Writing This - 2 year(s) ago
Seems like just yesterday that my wonderful editors at NEJM Journal Watch helped me write a piece marking this site’s 10-year anniversary. But no — that was 5 years ago. Yikes. Let’s see, what happened since the spring of 2018 that is relevant to this place: 216 posts. According to our crack research team, that’s one every 8.449074 […]
Source: HIV and ID ObservationsCategories: Healthcare Professionals, Latest HeadlinesTweet-
This blog-column-newletter (or whatever you want to call it) on NEJM @JWatch is 15 years old. A brief reflection on why I keep writing it, plus a quick look back at the previous 5 years ... did something notable in ID happen during that time? 😉 https://t.co/wnNMKfucKJ
-
I have a quick question https://t.co/bvXTT3CawZ https://t.co/Un2mufWwtc https://t.co/y1kgkvI1ru